Synergy Flaunts Constipation Data From Linzess Challenger
Synergy Pharmaceuticals, which is waiting on a decision from the US FDA on its constipation drug plecanatide, provided additional data from two pivotal Phase III trials at Digestive Disease Week (DDW) in San Diego recently. The product will go up against Linzess, which is marketed by Allergan and Ironwood Pharmaceuticals, and is expected to compete on its better side effect profile.
You may also be interested in...
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
The latest drug development news and highlights from our FDA Performance Tracker.
Plecanatide met the primary endpoint in first Phase III trial in irritable bowel syndrome with constipation, with less incidence of diarrhea than seen in Linzess trials. Synergy is awaiting approval in chronic idiopathic constipation and appears on pace to file an sNDA in IBS-C during the first quarter.
Positive topline results from the first of two pivotal Phase III trials of Synergy Pharmaceuticals' chronic idiopathic constipation drug plecanatide have sent the company's share price soaring.